

## BlueShield. BAVENCIO Federal Employee Program. PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

| Patient Information (required)              |  |                          | Provider Information (required)  |               |                 |                |
|---|--|--------------------------|--|---------------|-----------------|----------------|
| Date:                                       |  |                          | Provider Name:   |               |                 |                |
| Patient Name:                               |  |                          | Specialty:   |               | NPI:            |                |
| Date of Birth: Sex:  Male Female            |  | Female                   | Office Phone:  |               | Office Fax:     |                |
| Street Address:                             | I  |                          | Office Street Address:   |               | <u>I</u>        |                |
| City:                                       | State:   | Zip:                     | City:  | Sta           | ate:            | Zip:           |
| Patient ID: R                               |  | ]                        | Physician Signature:   |               |                 |                |
| N   | P  | HYSICIAN C               | COMPLETES  |               |                 |                |
|   |  | Bavencio                 | (avelumab)   |               |                 |                |
| ,   | **Check www.fepblue.org/form                             |                          | ` '  | the patient's | benefit         |                |
|   | <b>NOTE</b> : Form m                                     | ust be complete          | d in its <b>entirety</b> for prod  | cessing       |                 |                |
| Is this request for brand or                | generic? □Brand □G                                       | eneric                   |  |               |                 |                |
| <ol> <li>Has the patient been on</li> </ol> | Bavencio continuously fo                                 | or the last <b>6 mon</b> | ths, excluding samples   | ? Please se   | elect answer l  | below:         |
| □NO – this is INITIA                        | TION of therapy, please a                                | answer the follo         | wing question(s):  |               |                 |                |
| a. What is the patie                        | ent's diagnosis?   |                          |  |               |                 |                |
| ☐ Advanced Re                               | enal Cell Carcinoma (RCC                                 | C)                       |  |               |                 |                |
| i. Will Bav                                 | encio be used in combinat                                | tion with Inlyta         | (acitinib)? The same of the sa | 10            |                 |                |
| ii. Will live                               | er enzymes be monitored?                                 | □Yes □No                 |  |               |                 |                |
| iii. Will the                               | e patient be monitored for                               | cardiovascular e         | events?  \( \subseteq \text{Yes} \) \( \subseteq \text{No} \)  |               |                 |                |
| iv. Will Ba                                 | vencio be used as first-line                             | e treatment? 🗖           | Yes □No  |               |                 |                |
| ☐ Locally adva                              | nced or metastatic urothel                               | ial carcinoma            |  |               |                 |                |
| i. Has the p                                | patient had disease progres                              | sion with first-l        | ine platinum-containing  | g chemothe    | erapy? 🗆Yes     | s □No*         |
| * <b>I</b> f N(                             | O, will Bavencio be used a                               | s maintenance t          | reatment?  \( \subseteq \text{Yes} \)  | 0             |                 |                |
| ii. Has the                                 | patient had disease progre                               | ssion during or          | following platinum-con   | taining cho   | emotherapy?     | □Yes □No*      |
|   | O, has the patient had disea<br>num-containing chemother |                          |  | oadjuvant (   | or adjuvant tr  | eatment with   |
| ☐ Metastatic M                              | Ierkel Cell Carcinoma (MC                                | CC)                      |  |               |                 |                |
| ☐ Other diagno                              | sis (please specify):                                    |                          |  |               |                 |                |
| ☐ YES - this is a PA re                     | enewal for <b>CONTINUAT</b>                              | ION of therapy,          | please answer the follo  | wing ques     | tions:          |                |
| a. What is the patie                        |  |                          |  |               |                 |                |
| ☐ Advanced Re                               | enal Cell Carcinoma (RCC                                 | C)                       |  |               |                 |                |
| i. Will Bav                                 | encio be used in combinat                                | tion with Inlyta         | (acitinib)? The same of the sa | 10            |                 |                |
| ii. Will live                               | er enzymes be monitored?                                 | □Yes □No                 |  |               |                 |                |
| iii. Will the                               | e patient be monitored for                               | cardiovascular e         | events?  \( \subseteq \text{Yes} \) \( \subseteq \text{No} \)  |               |                 |                |
| ☐ Locally adva                              | nced or metastatic urothel                               | ial carcinoma            |  |               |                 |                |
| ☐ Metastatic M                              | Ierkel Cell Carcinoma (MC                                | CC)                      |  |               |                 |                |
| ☐ Other diagno                              | osis (please specify):                                   |                          |  |               |                 |                |
| b. Has the patient e                        | experienced disease progre                               | ession or unacce         | ptable toxicity while on   | Bavencio      | therapy?        | Yes □No        |
| 2. Will the patient be mon                  | itored for all immune-med                                | liated adverse re        | eactions and will therapy  | y discontir   | nued if necess  | sary? □Yes □No |
| 3. <b>FEMALE Patient</b> : Is t             |  |                          |  |               |                 |                |
|   | ient be advised to use effe                              | =                        |  | th Bavenci    | io and for at l | east one month |



## BlueShield. BAVENCIO Federal Employee Program. PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

Message:

Attached is a Prior Authorization request form.

For your convenience, there are 3 ways to complete a Prior Authorization request:

| Electronically Online (ePA) Results in 2-3 minutes FASTEST AND EASIEST | Now you can get responses to drug Prior Authorization requests <b>securely</b> online. <b>Online</b> submissions may receive <b>instant</b> responses and do not require faxing or phone calls.  Requests can be made 24 hours a day, 7 days a week. For more information on electronic prior authorization (ePA) and to register, go to <b>Caremark.com/ePA.</b>                     |
|--|---|
| Phone (4-5 minutes for response)                                       | The FEP Clinical Call Center can be reached at (877)-727-3784 between the hours of 7AM-9PM Eastern Time. A live representative will assist with the Prior Authorization, asking for the same information contained on the attached form. Please review the form and have your answers ready for faster service.  The process over the phone takes on average between 4 and 5 minutes. |
| Fax (3-5 days for response)  | Fax the attached form to (877)-378-4727. Requests sent via fax will be processed and responded to within 5 business days. The form must be filled out completely, if there is any missing information the Prior Authorization request cannot be processed.  Please only fax the completed form once as duplicate submissions may delay processing times.                              |

faster... easier... better...

Introducing ePA! Online Prior
Authorizations in minutes through
Caremark.com/ePA. Sign up today!

CVS/caremark<sup>-</sup>

